Literature DB >> 29411547

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.

S Louis Bridges1, Douglas W White2, Angus B Worthing3, Ellen M Gravallese4, James R O'Dell5, Kamala Nola6, Jonathan Kay4, Stanley B Cohen7.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29411547     DOI： 10.1002/art.40388

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  10 in total

Review 1.  Focus on biosimilar etanercept - bioequivalence and interchangeability.

Authors:  Fabrizio Cantini; Maurizio Benucci
Journal:  Biologics       Date:  2018-08-30

2.  Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.

Authors:  Yifei Liu; Min Yang; Vishvas Garg; Eric Q Wu; Jessie Wang; Martha Skup
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 3.  Emerging B-Cell Therapies in Systemic Lupus Erythematosus.

Authors:  Ayse Bag-Ozbek; Joyce S Hui-Yuen
Journal:  Ther Clin Risk Manag       Date:  2021-01-14       Impact factor: 2.423

Review 4.  Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

Authors:  Eduardo Mysler; Valderilio Feijó Azevedo; Silvio Danese; Daniel Alvarez; Noriko Iikuni; Beverly Ingram; Markus Mueller; Laurent Peyrin-Biroulet
Journal:  Drugs       Date:  2021-10-27       Impact factor: 9.546

5.  Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations.

Authors:  Kayoko Kaneko; Daniel Prieto-Alhambra; Clare Jacklin; Ailsa Bosworth; Sally Dickinson; Sarah Berry; Helen McAteer; Peter C Taylor
Journal:  BMJ Open       Date:  2022-02-16       Impact factor: 2.692

6.  Guizhi-Shaoyao-Zhimu decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NF-κB signalling to suppress osteoclastogenesis.

Authors:  Shu-Jun Wei; Qing Zhang; Yong-Jing Xiang; Lan-Yu Peng; Wei Peng; Qiang Ren; Yong-Xiang Gao
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

7.  The Importance of Countering Biosimilar Disparagement and Misinformation.

Authors:  Hillel P Cohen; Dorothy McCabe
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

8.  Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.

Authors:  William D Renton; Helen Leveret; Catherine Guly; Heather Smee; Jamie Leveret; Athimalaipet V Ramanan
Journal:  Pediatr Rheumatol Online J       Date:  2019-10-04       Impact factor: 3.054

Review 9.  Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?

Authors:  Daniel F Alvarez; Gertjan Wolbink; Carol Cronenberger; John Orazem; Jonathan Kay
Journal:  BioDrugs       Date:  2020-12       Impact factor: 5.807

10.  Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.

Authors:  Maria Chiara Ditto; Simone Parisi; Marta Priora; Silvia Sanna; Clara Lisa Peroni; Angela Laganà; Antonio D'Avolio; Enrico Fusaro
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.